In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on BioNTech SE (BNTX – Research Report), with a price ...

BioNTech SE (NASDAQ:BNTX), a biotechnology company renowned for its mRNA technology platform and COVID-19 vaccine success, is navigating a crucial phase in its evolution. With a market capitalization ...

BioNTech SE has moved 10.6% over the last year compared to 25.6% for the S&P 500 -- a difference of -15.0% BNTX has an average analyst rating of buy and is -7.87% away from its mean target price of ...

Ahead of his confirmation hearing this week, Robert F. Kennedy Jr., President Donald Trump’s nominee for HHS Secretary, has ...

PFE's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the ...

Atomi Financial Group Inc. raised its stake in BioNTech SE (NASDAQ:BNTX – Free Report) by 6.7% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional ...

We rate BioNTech SE a hold due to volatile performance, weak growth, and premium valuation amidst COVID-19 vaccine reliance.

Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.

The average of price targets set by Wall Street analysts indicates a potential upside of 25.6% in BioNTech (BNTX). While the effectiveness of this highly sought-after metric is questionable, the ...

Check a company’s competitiveness in the job market with alternative data that tracks hiring, job openings, and more.

Leverage fair value analysis to evaluate the market value of stocks enabling more informed investment decisions.

EBITDA is earnings before interest, tax, depreciation, and amortisation. The company proposed a capital expenditure of Rs 400 crore to enhance the production capacity at its plant located in ...